These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 11270618

  • 1. The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice.
    Tsuji M, Takeda H, Matsumiya T, Nagase H, Narita M, Suzuki T.
    Life Sci; 2001 Mar 02; 68(15):1717-25. PubMed ID: 11270618
    [Abstract] [Full Text] [Related]

  • 2. Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (-)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice.
    Takasaki I, Suzuki T, Sasaki A, Nakao K, Hirakata M, Okano K, Tanaka T, Nagase H, Shiraki K, Nojima H, Kuraishi Y.
    J Pharmacol Exp Ther; 2004 Apr 02; 309(1):36-41. PubMed ID: 14711930
    [Abstract] [Full Text] [Related]

  • 3. Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats.
    Mori T, Nomura M, Nagase H, Narita M, Suzuki T.
    Psychopharmacology (Berl); 2002 Apr 02; 161(1):17-22. PubMed ID: 11967626
    [Abstract] [Full Text] [Related]

  • 4. The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice.
    Tsuji M, Yamazaki M, Takeda H, Matsumiya T, Nagase H, Tseng LF, Narita M, Suzuki T.
    Eur J Pharmacol; 2000 Apr 07; 394(1):91-5. PubMed ID: 10771039
    [Abstract] [Full Text] [Related]

  • 5. TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys.
    Endoh T, Tajima A, Izumimoto N, Suzuki T, Saitoh A, Suzuki T, Narita M, Kamei J, Tseng LF, Mizoguchi H, Nagase H.
    Jpn J Pharmacol; 2001 Mar 07; 85(3):282-90. PubMed ID: 11325021
    [Abstract] [Full Text] [Related]

  • 6. Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist.
    Endoh T, Matsuura H, Tajima A, Izumimoto N, Tajima C, Suzuki T, Saitoh A, Suzuki T, Narita M, Tseng L, Nagase H.
    Life Sci; 1999 Mar 07; 65(16):1685-94. PubMed ID: 10573186
    [Abstract] [Full Text] [Related]

  • 7. A novel kappa-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice.
    Tsuji M, Takeda H, Matsumiya T, Nagase H, Yamazaki M, Narita M, Suzuki T.
    Life Sci; 2000 Mar 07; 66(25):PL353-8. PubMed ID: 10894094
    [Abstract] [Full Text] [Related]

  • 8. Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions.
    Suzuki T, Izumimoto N, Takezawa Y, Fujimura M, Togashi Y, Nagase H, Tanaka T, Endoh T.
    Brain Res; 2004 Jan 09; 995(2):167-75. PubMed ID: 14672806
    [Abstract] [Full Text] [Related]

  • 9. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
    Mizoguchi H, Hung KC, Leitermann R, Narita M, Nagase H, Suzuki T, Tseng LF.
    Eur J Pharmacol; 2003 Feb 07; 461(1):35-9. PubMed ID: 12568913
    [Abstract] [Full Text] [Related]

  • 10. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system.
    Umeuchi H, Togashi Y, Honda T, Nakao K, Okano K, Tanaka T, Nagase H.
    Eur J Pharmacol; 2003 Sep 05; 477(1):29-35. PubMed ID: 14512095
    [Abstract] [Full Text] [Related]

  • 11. Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models.
    Yoshikawa S, Hareyama N, Ikeda K, Kurokawa T, Nakajima M, Nakao K, Mochizuki H, Ichinose H.
    Eur J Pharmacol; 2009 Mar 15; 606(1-3):102-8. PubMed ID: 19374836
    [Abstract] [Full Text] [Related]

  • 12. [Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis].
    Nakao K, Ikeda K, Kurokawa T, Togashi Y, Umeuchi H, Honda T, Okano K, Mochizuki H.
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Apr 15; 28(2):75-83. PubMed ID: 18516986
    [Abstract] [Full Text] [Related]

  • 13. Direct evidence for the involvement of the mesolimbic kappa-opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state.
    Narita M, Kishimoto Y, Ise Y, Yajima Y, Misawa K, Suzuki T.
    Neuropsychopharmacology; 2005 Jan 15; 30(1):111-8. PubMed ID: 15257306
    [Abstract] [Full Text] [Related]

  • 14. Effects of Intrathecal κ-Opioid Receptor Agonist on Morphine-Induced Itch and Antinociception in Mice.
    Sakakihara M, Imamachi N, Saito Y.
    Reg Anesth Pain Med; 2016 Jan 15; 41(1):69-74. PubMed ID: 26587674
    [Abstract] [Full Text] [Related]

  • 15. Characterization of the antinociceptive effects of TRK-820 in the rat.
    Endoh T, Tajima A, Suzuki T, Kamei J, Narita M, Tseng L, Nagase H.
    Eur J Pharmacol; 2000 Jan 10; 387(2):133-40. PubMed ID: 10650153
    [Abstract] [Full Text] [Related]

  • 16. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820.
    Togashi Y, Umeuchi H, Okano K, Ando N, Yoshizawa Y, Honda T, Kawamura K, Endoh T, Utsumi J, Kamei J, Tanaka T, Nagase H.
    Eur J Pharmacol; 2002 Jan 25; 435(2-3):259-64. PubMed ID: 11821035
    [Abstract] [Full Text] [Related]

  • 17. Effect of the highly selective and nonpeptide delta opioid receptor agonist TAN-67 on the morphine-induced place preference in mice.
    Suzuki T, Tsuji M, Mori T, Misawa M, Endoh T, Nagase H.
    J Pharmacol Exp Ther; 1996 Oct 25; 279(1):177-85. PubMed ID: 8858991
    [Abstract] [Full Text] [Related]

  • 18. Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan.
    Nagase H, Hayakawa J, Kawamura K, Kawai K, Takezawa Y, Matsuura H, Tajima C, Endo T.
    Chem Pharm Bull (Tokyo); 1998 Feb 25; 46(2):366-9. PubMed ID: 9501472
    [Abstract] [Full Text] [Related]

  • 19. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
    Ikeda K, Yoshikawa S, Kurokawa T, Yuzawa N, Nakao K, Mochizuki H.
    Eur J Pharmacol; 2009 Oct 12; 620(1-3):42-8. PubMed ID: 19686730
    [Abstract] [Full Text] [Related]

  • 20. Combination of Clinically Utilized Kappa-Opioid Receptor Agonist Nalfurafine With Low-Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice.
    Zhou Y, Kreek MJ.
    Alcohol Clin Exp Res; 2019 Jun 12; 43(6):1077-1090. PubMed ID: 30908671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.